MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID BIOPSY WITH DIAGNOSTIC IMAGING
PERSPECTIVE MONOCENTRIC STUDY: USE OF LIQUID BIOPSY AND DIAGNOSTIC IMAGING IN THE SEARCH FOR CIRCULATING TUMOR DNA IN PATIENTS WITH BREAST CANCER
1 other identifier
observational
200
1 country
1
Brief Summary
Evaluation of the diagnostic accuracy of Mammography in the morpho-structural analysis of mammographic images in breast cancer-diagnosed patients or patients in follow-up for breast cancer by extracting a number of features describing the texture and morphology of the lesions reported in the form of a structured report explicitly developed for the study. Correlation of the data obtained from evaluating the primary endpoint with the genetic/molecular analysis on liquid biopsy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 12, 2022
CompletedFirst Submitted
Initial submission to the registry
November 12, 2022
CompletedFirst Posted
Study publicly available on registry
November 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 22, 2025
CompletedNovember 21, 2022
November 1, 2022
1 year
November 12, 2022
November 12, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Radiomic of breast cancers and liquid biopsy
Detect possible relationships between breast cancers radiomic feature and genetic mutations on liquid biopsy
36 months
Interventions
Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
Eligibility Criteria
The liquid biopsy will be performed on all patients who undergo a mammography examination in which a malignant focal aspect has been found and who agree to participate in the study. All patients enrolled in the study will be subjected to a peripheral venous blood sample. The ctDNA will be extracted for molecular analysis and will be performed with NGS (Next Generation Sequencing) technology.
You may qualify if:
- full information on the study and signature of the informed consent
- biopsy-proven breast cancer or previous surgery for breast cancer
- willingness of the patient to undergo liquid biopsy
You may not qualify if:
- state of pregnancy or breastfeeding
- patients operated on for benign or inflammatory diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University "Luigi Vanvitelli"
Naples, 80127, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Researcher
Study Record Dates
First Submitted
November 12, 2022
First Posted
November 21, 2022
Study Start
September 12, 2022
Primary Completion
September 15, 2023
Study Completion
September 22, 2025
Last Updated
November 21, 2022
Record last verified: 2022-11